BackBioXcel Therapeutics Overview

BioXcel Therapeutics Minority Interest

Latest minority interest for BTAI: $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

BioXcel Therapeutics Minority Interest History

Loading

BioXcel Therapeutics vs. peers: Minority Interest Comparison

Loading

BioXcel Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BioXcel Therapeutics (BTAI) FAQ

BioXcel Therapeutics's minority interest stands at $0 as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BioXcel Therapeutics reported $0 in minority interest versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in minority interest can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how BioXcel Therapeutics's minority interest evolved across reporting periods, while the comparison chart places BTAI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, minority interest is commonly used to spot outliers. BioXcel Therapeutics's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.